Concepedia

John L. Langowski

JL

Statistics

Publications

15

Citations

2.7K

H-Index

14

Active since

1996

Affiliations

Nektar Therapeutics (United States)(Current)

Novartis (Switzerland)

Novartis Institutes for BioMedical Research

Palo Alto University

Dana-Farber Cancer Institute

John L. Langowski is an author at Nektar Therapeutics (United States) specializing in oncology, cancer immunotherapy, and medicine.

Publications per year

1996–2021

15

Publications

15

IL-23 promotes tumour incidence and growth

John L. Langowski, Xueqing Zhang, Lingling Wu et al. · Nature · 2006 · 996 citations

, , +12

IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance

John B. Mumm, Jan Emmerich, Xueqing Zhang et al. · Cancer Cell · 2011 · 414 citations · Full text

, , +10

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models

Deborah H. Charych, Ute Hoch, John L. Langowski et al. · Clinical Cancer Research · 2016 · 392 citations

, , +17

Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation

Jing Lü, Tatiana Zavorotinskaya, Yumin Dai et al. · Blood · 2013 · 161 citations · Full text

, , +8

Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy

Deborah H. Charych, Samira Khalili, Vidula Dixit et al. · PLoS ONE · 2017 · 144 citations · Full text

, , +16

1–5 of 15